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In the developed world, the majority of new and existing hepatitis C virus (HCV) infections occur among
people who inject drugs (PWID). The burden of HCV-related liver disease in this group is increasing, but treat-
ment uptake among PWID remains low. Among PWID, there are a number of barriers to care that should be
considered and systematically addressed, but these barriers should not exclude PWID from HCV treatment.
Furthermore, it has been clearly demonstrated that HCV treatment is safe and effective across a broad range of
multidisciplinary healthcare settings. Given the burden of HCV-related disease among PWID, strategies to
enhance HCV assessment and treatment in this group are urgently needed. These recommendations demon-
strate that treatment among PWID is feasible and provides a framework for HCV assessment, management,
and treatment. Further research is needed to evaluate strategies to enhance assessment, adherence, and SVR
among PWID, particularly as new treatments for HCV infection become available.
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In the developed world, 50%–80% of hepatitis C virus
(HCV) infection is among people who inject drugs
(PWID) [1]. Hereafter, “PWID” will refer to people
with current or “active” injection drug use (IDU),
which is generally deﬁned as use in the past 6 months,
and to former injectors who are still active non–
injection drug users and/or on opioid substitution
therapy (OST). The natural history of HCV (increase in
liver cirrhosis after 15–20 years), and an aging cohort
of PWID, means that a large burden of advanced liver
disease is anticipated in the next decade [2].
Until recently, HCV treatment guidelines excluded
PWID, due to concerns about poor adherence, adverse
events, and reinfection [3]. Successful HCV treatment
studies among PWID challenged this paradigm [4–35],
and guidelines have been revised to consider HCV treat-
ment among PWID on a “case-by-case” basis [36–38].
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Despite revised guidelines, few PWID have received HCV
treatment [39–42]. Enhanced HCV assessment and treatment
in PWID will be required to reduce future HCV-related mor-
bidity and mortality [43]. The availability of effective, tolerable,
and simpler direct-acting antivirals (DAAs) should improve
the feasibility of this approach. The International Network of
Hepatitis in Substance Users established an expert panel to
develop recommendations to enhance HCV assessment, man-
agement, and treatment among PWID.
METHODS
The recommendations have been graded according to the Grad-
ing of Recommendations Assessment, Development, and Evalu-
ation (GRADE) system, [38]. The strength of recommendations
reﬂects the quality of underlying evidence (Table 1). The quality
of the evidence has been classiﬁed in 1 of 3 levels: high (A), mod-
erate (B), or low (C). The GRADE system offers 2 grades of
recommendation: strong (1) or weak (2).
Epidemiology and Prevention of HCV
Prevalence of HCV among PWID is 65% [44] and >80%
among long-term PWID [45]. HCV genotypes 1a, 1b, and 3a
are common among PWID [46]. Genotype 4d is common
among PWID in Europe [47], and 6 in Southeast Asia [48]. In-
cidence of HCV in PWID is 2%–45% per annum [45]. High
coverage of combined harm reduction programs (opioid substi-
tution treatment [OST] and needle exchange programs) can
reduce HCV incidence [49–51]. Modeling studies suggest that
HCV treatment for PWID could reduce transmission [52].
Recommendations
1. PWID should be routinely and voluntarily tested for
HCV antibodies/RNA and if negative, every 6–12 months (B1).
2. PWID should be provided with clean drug injecting
equipment and access to OST as part of widespread compre-
hensive harm reduction programs, including in prisons (B1).
Natural History of HCV and Effects of Drugs on the Liver
Chronic HCV infection develops in 75% [53], with 10%–20%
developing cirrhosis over 20–30 years of infection [2]. In a
meta-analysis of HCV-infected PWID, the 20-year cirrhosis
prevalence was 15% [54]. Despite slow HCV disease progres-
sion over the initial 20 years of infection, factors contributing
to ﬁbrosis progression include age, continued moderate to
heavy alcohol use, human immunodeﬁciency virus (HIV) in-
fection, obesity, and insulin resistance (reviewed in [2]).
Despite misconceptions among affected populations and
healthcare workers, no liver toxicity is reported for heroin [55]
or methadone [56]. Buprenorphine occasionally increases
transaminases [57]. Methylenedioxymethamphetamine rarely
causes acute liver failure due to direct liver toxicity [58, 59], and
little is known about methamphetamine-related liver toxicity [60].
Heavy alcohol consumption is associated with a higher risk of
cirrhosis [61]. Tobacco [62] and daily cannabis [63, 64] smoking
may increase ﬁbrosis progression, but further studies are
needed. Coffee consumption is associated with lower necroin-
ﬂammatory activity and less-advanced ﬁbrosis [65, 66].
Aging cohorts of PWID with chronic HCV and low treat-
ment uptake are currently leading to an increasing burden of
HCV-related morbidity and mortality [2]. In several countries
where PWID are the major population affected by HCV, 20%–
25% of deaths among HCV-infected individuals are from liver
disease and 15%–30% are from drug-related causes [2].
Recommendations
1. PWID should be counseled to moderate alcohol intake, or
abstain if there is evidence of advanced liver disease (A1).
2. PWID should be counseled to moderate cannabis use, or
abstain if there is evidence of advanced liver disease (B2).
3. Cessation of injecting is not required to limit HCV
disease progression (B2).
4. The potential impact of drug use on the liver should be
discussed with PWID (C2).
Table 1. Evidence Grading (Adapted From the GRADE System)
Evidence Notes
Quality of
Evidence/
Grade
High quality Further research is very
unlikely to change our
confidence in the estimate
of effect.
A
Moderate
quality
Further research is likely to
have an important impact on
our confidence in the
estimate of effect and may
change the estimate.
B
Low quality Further research is very likely
to have an important impact
on our confidence in the
estimate of effect and is
likely to change the
estimate. Any change of
estimate is uncertain.
C
Recommendation Notes
Strong Factors influencing the
strength of the
recommendation included
the quality of the evidence,
presumed patient-important
outcomes, and cost.
1
Weak Variability in preferences and
values, or more uncertainty.
Recommendation is made
with less certainty, higher
cost, or resource
consumption.
2
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Noninvasive Liver Fibrosis Assessment
Liver biopsy is the gold standard for liver ﬁbrosis assessment,
but it is invasive and logistically difﬁcult. As per international
guidelines [37, 38], noninvasive methods such as transient elas-
tography or well-established panels of biomarkers of ﬁbrosis
are acceptable for liver disease assessment. Noninvasive meth-
ods have excellent utility for the identiﬁcation of HCV-related
cirrhosis, but lesser accuracy for earlier stages [67], and can
predict HCV-related survival [68]. Combining multiple modal-
ities achieves the best performance [69]. Noninvasive tests are
cost-effective [70]. Among PWID, transient elastography can
enhance liver disease screening [71, 72].
Recommendations
1. Noninvasive assessments have a reduced risk and greater
acceptance than liver biopsy, may enhance HCV screening and
disease assessment among PWID, and should be offered, if
available (B1).
2. Combining multiple noninvasive assessments is recom-
mended, when possible (B1).
Pretherapeutic Assessment
Guidelines for pretherapeutic assessment for those with HCV
are available [37, 38]. However, HCV-infected PWID have
complex social, medical, and psychiatric comorbidities, compli-
cating decisions around care (reviewed in [73]). Poor HCV
knowledge and inaccurate perceptions are barriers for accessing
care [74–77]. Factors associated with not receiving HCV treat-
ment include older age [78], minority ethnicity [78], ongoing or
former drug use [79–81], ongoing alcohol use [78, 79], ad-
vanced liver disease [80], comorbid diseases [78, 81], psychiatric
disease [78, 80], and OST [79].
Recommendations
1. Pretherapeutic education should include discussions of
HCV transmission, risk factors for ﬁbrosis progression, treat-
ment, reinfection risk, and harm reduction strategies (B1).
2. Pretherapeutic assessment should include an evaluation
of housing, education, cultural issues, social functioning and
support, ﬁnances, nutrition, and drug and alcohol use. PWID
should be linked to social support services and peer support, if
available (A1).
Indications for Treatment
The goal of HCV therapy is to prevent liver disease complica-
tions and death from HCV. The end point is sustained virologic
response (SVR), which equates to cure in >99% of patients.
SVR is associated with improved quality of life, regression of
ﬁbrosis, and reduced risk of complications in patients with
cirrhosis [82].
According to international guidelines [37, 38], individuals
with chronic HCV and absolute contraindications to standard
of care should not receive therapy.
Recommendations
1. PWID should receive HCV assessment, with treatment
decisions based on an individualized evaluation of social, life-
style, and clinical factors (B1).
2. PWID with absolute contraindications to standard of care
should not receive HCV therapy (B1).
Peginterferon and DAA-Based Treatment
In PWID, treatment of chronic HCV with pegylated interferon
alfa (peg-IFN)/ribavirin (RBV) is safe and effective [4–35], and
has been recommended for PWID by international guidelines
following individualized assessment [37, 38]. DAA therapy,
when added to peg-IFN/RBV, enhances treatment response for
chronic HCV genotype 1 [83–86]. Future DAAs in combination
with peg-IFN/RBV should provide improved efﬁcacy, tolerabili-
ty, dosing schedules, and therapy duration [87]. Evidence sug-
gests that IFN-free DAA-based regimens are likely to be
curative in a high proportion of individuals with chronic HCV
genotype 2/3 [88, 89] and 1 [90–92] infections.
DAA clinical development programs have excluded individuals
with active drug use, but many trials have included those on OST.
DAA-based safety and treatment outcome data have not been
presented on clinical trial subpopulations of individuals on OST.
Drug–drug interaction studies have been undertaken on tela-
previr and boceprevir with methadone [93, 94] and buprenor-
phine [94, 95], with no clinically important interactions observed.
Recommendations
1. Evaluation of safety and efﬁcacy of telaprevir and boce-
previr, in combination with peg-IFN/RBV, is required in PWID
with chronic HCV genotype 1 (C1).
2. Telaprevir and boceprevir can be used in PWID on OST
(B1).
3. Telaprevir and boceprevir do not require speciﬁc metha-
done and buprenorphine dose adjustment, but patients should
be monitored for signs of opioid toxicity or withdrawal (B1).
4. Consideration of telaprevir and boceprevir use in PWID
should be undertaken on an individualized basis, but those
with early liver disease should generally be advised to await
further data and/or potential development of improved DAA-
based therapies (B1).
Impact of Drug Use on Adherence and SVR
Adherence to HCV therapy is often deﬁned as receipt of ≥80%
of scheduled peg-IFN/RBV for ≥80% of the treatment period,
but this does not distinguish between missed doses and treat-
ment discontinuation [96]. Suboptimal peg-IFN exposure is
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driven by early treatment discontinuation as compared to
missed doses [97]. Both physicians [98] and individuals [99]
overestimate adherence to HCV therapy. Adherence [96, 97]
and treatment completion [96–98] are associated with SVR, but
the impact of missed doses on SVR is unclear [96, 97]. Among
PWID, adherence [29, 35, 97, 100] and treatment completion [97]
are associated with SVR.
Peg-IFN/RBV is safe and effective among those with a
history of IDU [4, 6–9, 11–35] and among active PWID [101],
with SVR of 54%–56% [4, 34, 101]. PWID often have character-
istics associated with favorable HCV treatment response, in-
cluding younger age, HCV genotype 3, and mild liver disease [9].
A history of IDU does not compromise adherence [97, 98, 102],
treatment completion [4, 21, 29, 97], or SVR [4], although
some studies have found lower treatment completion [4].
Recent drug use at treatment initiation has limited impact on
adherence [29, 30, 97, 98, 100, 103], treatment completion [4,
28, 29, 97], or SVR [6, 7, 20, 24, 27–29, 35, 101]. Some studies
have reported lower treatment completion in patients with
recent drug use at treatment completion [4, 32]. HCV treatment
does not have an impact on drug dependency treatment or in-
crease drug use [17, 18]. Occasional drug use during treatment
does not seem to impact adherence [29, 35, 97, 100], treatment
completion [29, 97, 104], or SVR [7, 29, 35]. However, lower ad-
herence [97, 98] and SVR [19, 20, 24] have been observed in
persons with frequent drug use (daily/every other day) during
treatment. When discontinuation occurs, it often occurs early
during therapy [18, 97]. In adherent PWID, alcohol use does not
impact SVR [105, 106].
Factors independently associated with adherence and treat-
ment completion among PWID include lower education and
unstable housing [97]. Factors independently associated with
lower SVR among PWID include poor social functioning [7], a
history of untreated depression [33], and ongoing drug use
during treatment [33].
Recommendations
1. Adherence should consider missed doses and treatment
discontinuation (B1).
2. PWID should be counseled on the importance of adher-
ence in attaining SVR (A1).
3. HCV treatment can be considered for PWID, provided
they wish to receive treatment and are able and willing to main-
tain regular appointments (A1).
4. A history of IDU and recent drug use at treatment initia-
tion are not associated with reduced SVR, and decisions to treat
must be made on a case-by-case basis (B1).
5. PWID with ongoing social issues or history of psychiatric
disease and those with more frequent drug use during therapy
are at risk of lower adherence and SVR and need to be moni-
tored closely during therapy (B1).
Impact of Mental Health on Adherence and SVR
As reviewed in [107], psychiatric comorbidity is high among
PWID. However, PWID do not have an increased risk for the
development of major depression during peg-IFN treatment.
Poorer social functioning is associated with new-onset depres-
sion during peg-IFN treatment [108]. Psychiatric comorbidity
is not associated with lower adherence, treatment completion,
SVR, or depression during peg-IFN treatment [26, 108–113].
As reviewed in [107], psychiatric contraindications to HCV
therapy include acute major and uncontrolled psychiatric
disorders. Although data are conﬂicting, studies show that
prophylactic antidepressants can reduce IFN-induced depres-
sion, particularly in patients with previous or ongoing depres-
sion [107]. Depression-speciﬁc symptoms are responsive to
serotonergic antidepressants [107]. Psychiatric adverse events
related to peg-IFN can be managed without dose adjustment or
discontinuation.
Recommendations
1. Pretreatment assessment should include an evaluation of
previous or current psychiatric illness, engagement with a drug
and alcohol counselor or psychiatrist, and discussions around
potential treatment options (A1).
2. If psychiatric comorbidities are present, decisions to treat
with peg-IFN must be made on a case-by-case basis (A1).
3. In cases of acute major and uncontrolled psychiatric disor-
ders, a pretreatment psychiatric assessment is recommended (C2).
4. Prophylactic antidepressants are recommended in cases
of a history of IFN-induced depression and with depressive
symptoms at baseline (B1).
Treatment Management
HCV treatment has been delivered successfully to PWID
through various models, including within hospital-based clinics,
drug detoxiﬁcation clinics, OST clinics, prisons, and communi-
ty-based clinics. As reviewed in [114], strategies that have been
successful for enhancing assessment, adherence, or SVR in-
clude hospital-based and primary care-based integrated care,
community-based telehealth, nurse-led education, psychoedu-
cation, directly observed therapy, peer support groups, and
peer support workers. The key basis for effective HCV clinical
management within these settings is access to a multidisciplin-
ary team, generally including clinician and nursing clinical
assessment and monitoring, drug and alcohol services, psychi-
atric services, and social work and other social support services
(including peer support, if available).
Recommendations
1. HCV treatment for PWID should be considered on an in-
dividualized basis and delivered within a multidisciplinary
team setting (B1).
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2. Access to harm reduction programs, social work, and
social support services should be a component of HCV clinical
management (B2).
3. Peer-based support should be evaluated as a means to
improve HCV clinical management (B2).
Reinfection Following Successful HCV Treatment
There is still some concern that reinfection due to recurrent
risk behaviors may negate potential beneﬁts of treatment. Re-
ported rates of reinfection following successful HCV treatment
among PWID are low, with estimates generally 1%–5% risk per
year (reviewed in [115]).
Recommendations
1. PWID should not be excluded from HCV treatment on
the basis of perceived risk of reinfection (B1).
2. Harm reduction education and counseling should be pro-
vided for PWID in the context of HCV treatment (B1).
3. Following SVR, monitoring for HCV reinfection through
annual HCV RNA assessment should be undertaken on PWID
with ongoing risk behavior (B2).
Treatment of Acute HCV
Acute HCV infection refers to the period spanning the ﬁrst 6
months following exposure to HCV [116]. Spontaneous clear-
ance occurs in 25% [53]. Peg-IFN–based SVR among HCV-
monoinfected PWID with acute HCV is 55%–74% (reviewed
in [116]), with treatment outcomes associated with adherence
and social support, but not IDU prior to or during treatment [7].
Recommendations
1. PWID with acute HCV symptoms should be monitored
for 12–16 weeks (including HCV RNA levels) to allow potential
spontaneous clearance (A1).
2. Peg-IFN monotherapy for 24 weeks should be considered
for PWID with acute HCV (B1).
3. Strategies to optimize adherence should be used in the
setting of acute HCV, with consideration of directly observed
peg-IFN therapy (B2).
HIV/HCV Coinfection
Prevalence of HCV among HIV-infected PWID is high
(>80%) [117]. Chronic HCV is the leading cause of non-AIDS
death where combination antiretroviral therapy (cART) is ac-
cessible [118]. Challenges with HIV/HCV include accelerated
HCV disease progression, potential cART-related liver toxicity,
multiple medication requirements, drug–drug interactions, and
medical comorbidities (reviewed in [119]). HIV/HCV is associ-
ated with a higher prevalence of psychiatric disorders, poverty,
homelessness, and incarceration [120]. HCV treatment re-
sponses may be poorer in those with HIV/HCV [121, 122].
Recommendations
1. HCV-infected PWID should be screened for HIV (B1).
2. The accelerated HCV disease progression in HIV/HCV
should be considered in treatment decision making (B2).
3. Potential drug–drug interactions between HIV, HCV, and
OST need to be considered (A1).
4. Early introduction of cART should be considered (B1).
Management of Hepatitis B Virus Coinfection
The global prevalence of chronic hepatitis B virus (HBV) is 8%
among PWID [44]. HBV vaccination is effective among PWID,
and accelerated schedules improve adherence [123]. Peg-IFN/
RBV is effective for the treatment of HCV in persons with
HBV/HCV [124]. Hepatitis D virus coinfection is frequent in
PWID [125]. Peg-IFN is the only effective drug [126].
Recommendations
1. PWID should be vaccinated for hepatitis A virus and
HBV (A1).
2. PWID with active HBV/HCV coinfection should be con-
sidered for peg-IFN/RBV therapy (B1).
Liver Transplantation
The proportion of people with a history of IDU undergoing
liver transplant for HCV-related cirrhosis or hepatocellular car-
cinoma is 5%–10% [127, 128]. Relapse to drug use following
transplant is rare [127, 128]. Selection criteria for liver trans-
plantation include 6–24 months of drug abstinence, controlled
psychiatric disease, and the presence of stable social support
networks [129]. OST is not a contraindication [127, 129, 130].
There are no data in PWID.
Recommendations
1. Awareness should be raised that liver transplant is a thera-
peutic option in those with a history of IDU (B2).
2. OST is not a contraindication for liver transplantation,
and individuals on OST should not be advised to reduce or
stop therapy (A1).
3. Psychiatric evaluation and follow-up should be offered to
PWID undergoing liver transplant (B1).
CONCLUSIONS
Given the burden of HCV-related disease among PWID, strate-
gies to enhance HCV assessment and treatment in this group
are urgently needed. These recommendations demonstrate that
treatment among PWID is feasible and provides a framework
for HCV assessment, management, and treatment. However,
many studies performed among PWID to date are limited,
given retrospective designs, small sample sizes, and lack of ran-
domized controlled trial design. Further research is needed to
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evaluate strategies to enhance assessment, adherence, and SVR
among PWID, particularly as new DAAs become available.
This will be crucial in the efforts to stem the burden of HCV-
related liver disease worldwide.
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